elotuzumab sold brand name empliciti humanized monoclonal antibody medication used combination lenalidomide dexamethasone adults received prior therapies treatment multiple also indicated adult patients combination pomalidomide dexamethasone received prior therapies including lenalidomide protease administration elotuzumab done intravenous injection elotuzumab premedicated dexamethasone diphenhydramine ranitidine developed bristol myers squibb common side effects elotuzumab lenalidomide dexamethasone includes fatigue diarrhea pyrexia constipation cough peripheral neuropathy nasopharyngitis upper respiratory tract infection decreased appetite common side effects elotuzumab pomalidomide dexamethasone includes constipation available information use elotuzumab pregnant elotuzumab immunostimulatory antibody targets signaling lymphocytic activation molecule family member two may granted breakthrough therapy designation us food drug administration fda multiple initial fda approval elotuzumab combination lenalidomide dexamethasone carried results illustrated eloquent may eceu gave similar furthermore results eloquent study led fda approval elotuzumab combination pomalidomide dexamethasone elotuzumab indicated adult patients combination treatment multiple myeloma patients received prior medical use multiple myeloma patients elotuzumab combined either lenalidomide dexamethasone pomalidomide package insert advises intravenous administration mgkg every week first cycles cycle days every weeks thereafter appropriate doses lenalidomide low dose dexamethasone acceptable additional information dosing dexamethasone andor lenalidomide refer package elotuzumab recommended intravenous administration mgkg week first cycles cycle start cycle administer mgkg every weeks administering recommended dose pomalidomide low dose additional information dosing dexamethasone andor dexamethasone refer package evaluate adverse reactions eloquent trial elotuzumab combined lenalidomide dexamethasone compared lenalidomide dexamethasone common adverse reactions higher denoted elotuzumab treated patients study similarly adverse reactions eloquent trial examined comparing elotuzumab combined pomalidomide dexamethasone pomalidomide dexamethasone elotuzumab immunostimulatory antibody targets signaling lymphocyte activation molecule family member also known cell surface glycoprotein present myeloma cells natural killer cells plasma cells subsets immune cells hematopoietic elotuzumab works activating natural killer cells along myeloma cells targeted flagged natural killer cellmediated destruction antibodydependent cellular trial elotuzumab therapy relapsed refractory multiple myeloma also known eloquent trial studied efficacy safety elotuzumab objective study determine addition elotuzumab lenalidomide dexamethasone would increase progression free survival patients refractory multiple randomized openlabel phase multicenter trial studied patients years older multiple myeloma measurable patients designated elotuzumab group control group elotuzumab group significant relative reduction risk disease progression median progressionfree survival elotuzumab group months compared months control additionally response rate etoluzumab group compared control group eloquent trial also known elotuzumab plus pomalidomide dexamethasone multiple myeloma patients refractory relapsed multiple myeloma refractory lenalidomide protease inhibitor randomized either elotuzumab group control elotuzumab group patients received elotuzumab pomalidomide dexamethasone control group patients received pomalidomide dexamethasone among patients failed treatment lenalidomide protease inhibitor death risk progression significantly lower elotuzumab study median progressionfree survival elotuzumab study arm months compared months control study group month follow httpsenwikipediaorgwikielotuzumab